Ping Fong Wu

US Patent:

20130315870, Nov 28, 2013

Filed:

Jun 29, 2011

Appl. No.:

13/807359

Inventors:

Shawn Edward Lupold - Ellicott City MD, US
Ping Wu - Baltimore MD, US
Ronald Rodriguez - Glenwood MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

C12N 15/86
C12N 15/10

US Classification:

424 932, 4353201, 506 9

Abstract:

The present invention relates to the field of viral gene therapy. More specifically, A the present invention provides compositions and methods for retargeting virus constructs. In one embodiment, the present invention provides an adenoviral construct comprising a nucleic acid encoding the peptide sequence MAE-X-PDP, wherein X is an antigen targeting peptide. In a more specific embodiment, an adenoviral construct comprises a nucleic acid sequence encoding the peptide sequence MAEWQPDTAHHWALTLPDP inserted into the HI-loop of adenovirus fiber protein. In yet another embodiment, the present invention provides a method for optimizing adenoviral infection of target cells comprising the steps of (a) generating a peptide-display adenovirus library, wherein the displayed peptide is a peptide that specifically binds an antigen expressed on the surface of a target cell, and wherein the displayed peptide is flanked by random peptide sequences; and (b) screening the peptide-display adenovirus library against the target cells.

US Patent:

20140017668, Jan 16, 2014

Filed:

Jun 30, 2011

Appl. No.:

13/807366

Inventors:

Shawn Edward Lupold - Ellicott City MD, US
Wasim Haider Chowdhury - Laurel MD, US
Ping Wu - Baltimore MD, US
Ronald Rodriguez - Glenwood MD, US

Assignee:

THE JOHNS HOPKINS UNIVERSITY - Baltimore MD

International Classification:

C12Q 1/68
C12N 15/86

US Classification:

435 5, 4353021

Abstract:

The present invention relates to the field of virology. More specifically, the present invention relates to the use of viral constructs to detect and quantify circulating tumor cells. In one embodiment, the present invention provides an adenovirus construct comprising (a) a cell type specific promoter that drives adenoviral replication; and (b) at least one reporter gene incorporated into the viral Major Late Transcriptional Unit. In another embodiment, an adenovirus construct comprises (a) prostate selective pro-basin promoter operably linked to the El gene; and (b) prostate specific antigen enhancer operably linked to the probasin promoter.